This cancer drug stock could double as its treatment hits the market, JPMorgan says
The investment bank initiated coverage with an overweight rating.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.